Kamada (KMDA) Enters Recombinant Human Alpha 1 Antitrypsin Development Agreement
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Kamada Ltd. (Nasdaq: KMDA) announced that it has signed a collaboration agreement with Yissum Research Development Company of the Hebrew University of Jerusalem, for the development of an efficient and robust eukaryotic expression system for recombinant human Alpha 1 Antitrypsin (rhAAT). The goal of this development work is to maximize protein yields and functionality.
The collaboration will be led by Dr. Tsafi Danieli, Head of the Protein Expression Facility at Hebrew University. Dr. Danieli has a vast amount of experience in recombinant DNA technologies and protein production systems.
“We are pleased to be working with the Hebrew University on the development of a recombinant human Alpha 1 Antitrypsin, as they are experts in recombinant DNA technologies and protein production systems,” said Amir London, Kamada’s Chief Executive Officer. “We initiated our development activities in the rhAAT field several years ago in preparation for future increased demand for AAT resulting from greater awareness of AAT deficiency, as well as potential additional indications for Alpha 1 Antitrypsin, which are currently in clinical development. Upon completion of the current work with Yissum, we intend to begin GMP-manufacturing scale up activities. Our collaboration with Yissum is intended to maintain our innovative global leadership in the area of AAT development in multiple indications.”
“The development of an effective recombinant human Alpha 1 Antitrypsin is an important undertaking and would address a significant unmet therapeutic development need,” said Yaacov Michlin, President and CEO of Yissum. “We are excited to collaborate with Kamada on this key project, as our work will result in expanding the range of new technologies and analytical methods essential for the development of therapeutic proteins.”
Kamada has previously developed analytical methods (physicochemical, biochemical, in-vitro, and in-vivo) that will help identify and characterize functional rhAAT. In addition, the Company has established a significant understanding of a favorable expression system and growth conditions required to successfully develop an effective rhAAT.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kamada (KMDA) Announces Positive Scientific Advice Response from CHMP on G1-AAT IV for aGvHD
- Simmons First National Corp (SFNC) to Acquire First Texas BHC for $462M
- Theravance Biopharma (TBPH) Reports Interim Data from TOUR Study in Oral Presentation at SCCM
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!